Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
December 15, 2018
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
Ravit Geva, Juanita Lopez, Sarah Danson, et al.
The EMBO Journal
|
July 12, 2002
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation
Zehavit Goldberg, Ronit Vogt Sionov, Michael Berger, et al.
Investigational New Drugs
|
December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.
Future Oncology (London, England)
|
September 4, 2024
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Ronnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, et al.
Molecular Oncology
|
April 21, 2026
CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3
Aya Saleh, Nitzan Medina-Itzhaki, Milena Chekov, et al.
The American Journal of Surgical Pathology
|
May 10, 2011
A comprehensive analysis of PAX8 expression in human epithelial tumors
Anna R Laury, Ruth Perets, Huiying Piao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.
Cancer Letters
|
November 22, 2020
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer
Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Journal for Immunotherapy of Cancer
|
April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma
Amaury Daste, Xiuning Le, Amani Makkouk, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
European Journal of Nuclear Medicine and Molecular Imaging
|
December 15, 2018
Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
Ravit Geva, Juanita Lopez, Sarah Danson, et al.
The EMBO Journal
|
July 12, 2002
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation
Zehavit Goldberg, Ronit Vogt Sionov, Michael Berger, et al.
Investigational New Drugs
|
December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.
Future Oncology (London, England)
|
September 4, 2024
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Ronnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, et al.
Molecular Oncology
|
April 21, 2026
CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3
Aya Saleh, Nitzan Medina-Itzhaki, Milena Chekov, et al.
The American Journal of Surgical Pathology
|
May 10, 2011
A comprehensive analysis of PAX8 expression in human epithelial tumors
Anna R Laury, Ruth Perets, Huiying Piao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.
Cancer Letters
|
November 22, 2020
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer
Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Journal for Immunotherapy of Cancer
|
April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma
Amaury Daste, Xiuning Le, Amani Makkouk, et al.
Page
of 4